Highly variable medicines - specific aspects of bioequivalence studies

At present a specific group of medicines - highly variable medicines - is distinguished based on intraindividual variability data (CV_intra > 30%). It is quite difficult to confirm therapeutic equivalence of highly variable medicines by pharmacokinetic bioequivalence studies, and quite a large number of subjects need to be included into the study in order to confirm bioequivalence within standard limits of 80-125%. Variability may be caused by many factors which include physiological and pathophysiological differences in absorption and metabolism processes; factors associated with properties of the active substance and factors associated with the finished product. In general factors impacting variability in bioequivalence studies could be divided into controllable and uncontrollable. The influence of controllable factors can be neutralized by proper performance of the bioequivalence study or proper development of the finished product. The influence of uncontrollable factors cannot be neutralized, and due to these factors medicines can be recognized as highly variable. This article provides a definition of a highly variable medicine, describes reasons for high variability and outlines current regulatory recommendations for and approaches to studying bioequivalence of highly variable medicines, proposes recommendations for designing such studies.

исследования биоэквивалентности, биоэквивалентность, высоковариабельные препараты, bioequivalence studies, bioequivalence, highly variable medicines

1. Shah VP, Yacobi A, Barr WH, Benet LZ, Breimer D, et al. Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res. 1996; (13): 1590–4.

2. Davit BM, Chen ML, Conner DP, Haidar SH, Kim S, Lee CH, et al. Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration. The AAPS J. 2012; 14(4): 915–24.

3. Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, et al. Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. The AAPS J. 2008; (10): 148–56.

4. Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther. 2005; (43): 485–498.

5. Zhou D. and Qiu Y. Understanding Biopharmaceutics Properties for Pharmaceutical Product Development and Manufacturing I – Oral Absorption and the Biopharmaceutics Classification System. J Validation Tech. 2009; 15(4): 62–72.

6. On Amendments to the Federal Law «On Circulation of Medicines». The Federal Law of 22.12.2014 № 429-FZ (in Russian).

7. On Amendments to the Federal Law «On Circulation of Medicines» and the Federal Law «On Amendments to the Federal Law “On Circulation of Medicines” ». The Federal Law of 13.07.2015 № 241-FZ (in Russian).

8. Conducting of qualitative studies of bioequivalence of medicines. Guidelines, approved by Ministry of Health and Social Development of the Russian Federation. Farmakokinetika i farmakodinamika 2005; 1(2): 14 (in Russian).

9. Zherdev VP, Kolyvanov GB, Litvin AA, Sariev AK. Harmonization of bioequivalence study of medicines: problems and possible solutions. Eksperimentalnaya i klinicheskaya farmakologiya 2003; 66(2): 60–64 (in Russian).

10. Investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.

11. Draft Guidance on Progesterone. United States Food and Drug Administration. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM209294.pdf.

12. Tothfalusi L, Endrenyi L, Arieta AG. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet. 2009; (48): 725–43.

13. Rules of bioequivalence study of drugs of the Eurasian Economic Union (version 2, 20.02.2015). Available from: http://www.eurasiancommission.org/ru/act/texnreg/deptexreg/konsultComitet/Documents (in Russian).

14. Hyslop T, Hsuan F, and Holder DJ. A small sample confidence interval approach to assess individual bioequivalence. Stat. Med. 2000; (19): 2885–97.

15. Tothfalusi L, Endrenyi L, Midha KK, Rawson MJ, Hubbard JW. Evaluation of the Bioequivalence of Highly-Variable Drugs and Drug Products. Pharmaceutical Research 2001; (18): 728–33.